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Background
α1 proteinase inhibitor (α1PI) belongs to the serin pro-
tease inhibitor (serpin) family; it is responsible for 90% of
the trypsin inhibitory capacity of human plasma. Its pri-
mary physiological role is to inhibit neutrophil elastase
that degrades elastin, collagen and proteoglycan and can
cause extensive lung damage. α1PI deficiency can result in
lung emphisema in adults, liver disease in children and is
also associated with cystic fibrosis, arthritis and other
malignant conditions [1-3]. Human plasma-derived α1PI
is a licensed product used for replacement therapy.
Although viral inactivation measures are taken, products
derived from human plasma carry the risk of contamina-
tion with blood-borne pathogens, and therefore recom-
binant is an attractive alternative.
α1PI exhibits a molecular mass of approximately 52 kD,
has 394 amino acids, a single cystein residue and three
carbohydrate attachment sites at asparagine residues 46,
83 and 247 [4,5]. Significant research effort was directed
to produce recombinant human α1PI in E. coli [6], yeast
[7], transgenic mice and sheep as well as plant cells [3]. E-
coli produced an unglycosylated product, the yeast pro-
duced incorrect glycosylation and the transgenic animals
pose the same threats as plasma derived product.
Results
Human α1PI was cloned and expressed in Aspergillus niger,
filamentous fungus that can grow in defined media and
had the ability to perform glycosylation. Submerged cul-
ture conditions were established: using starch as carbon
source, 30% dissolved oxygen concentration, pH 7.0 and
28°C; 10 mg per liter of active α1PI were secreted to the
growth media in 40 hours. Controlling the protein prote-
olysis was found to be an important factor in the produc-
tion from the fungus. The effect of carbon sources and
growth conditions on the production and stability of the
protein will be presented and evaluated.
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